降纤酶治疗不稳定型心绞痛疗效观察

目的：探讨降纤酶对不稳定型心绞痛（ＵＡＰ）的临床疗效。方法：在抗心绞痛常规疗法基础上，治疗组３０例用降纤酶１０ｕ静脉滴注，每天１次，共５ｄ；对照组３０例用脉络宁３０ｍｌ静脉滴注，每天１次，共１０ｄ，６ｄ后考核疗效及有关实验室指标。结果：治疗组、对照组的临床总有效率各为９６．６６％和７０％（Ｐ〈０．０１），期间治疗组的硝酸甘油用量、镇痛药使用次数较对照组少（Ｐ〈０．０１和０．０５）。治疗组治疗前后的

Clinical Effect of Treating Unstable Angina Pectoris with Defibrase

Objective: To investigate the clinical effects of treating unstable angina pectoris (UAP) with defibrase. Methods: Besides routine antiangina therapy, 30 cases of patients in the tested group were given defibrase 10 u with intravenous dripping, once daily for 5 days. 30 cases in the control group were given 30 ml of MaiLuoning instead of defibrase, intravenously dripped once daily for ten days. 6 days after the treatments, we took the clinical and laboratory results. Results: The clinical effective rates of the tested group and control group were 96.66% and 70%, respectively (P<0.01). During therapeutic period, the quantity and using times of nitroglycerin in the tested group were lower than those in the control group (P<0.01 and P<0.05, respectively). There were no significant changes in platelet count (PLT), plasma prothrombin time (PT) and activated partial thrombplastin time (APTT) while the fibrinogen (FIBEN) level reduced (P<0.01) in the tested group after treatment. Compared with before treatment, above indexes had no statistical differences in the control group. Conclusion: Defibrase is of ideal clinical effects for treating UAP. It is also safety and convenient to be used.